licensing in Biological Technology

NewBridge Pharmaceuticals Announces Licensing of Pylera(R) for Middle East, Africa, Turkey & Caspian Region

DUBAI, United Arab Emirates and SAN FRANCISCO, July 22 /PRNewswire/ -- NewBridge Pharmaceuticals, a specialty pharmaceutical, biologics, and medical device company serving the Middle East, Africa, Turkey & Caspian regions, today announced that it has entered into an exclusive license...

Transgenomic Completes Licensing Option With Dana-Farber Cancer Institute on Cold-PCR for Enrichment of DNA Mutations

OMAHA, Neb., April 7 /PRNewswire-FirstCall/ -- Transgenomic, Inc. (OTC Bulletin Board: TBIO), a leading global biotechnology company, announces that it has completed a licensing option with the Dana-Farber Cancer Institute, Boston, MA with regard to a method known as Cold-PCR. This variation of t...

AEterna Zentaris and Sanofi-Aventis Sign a Development, Commercialization and Licensing Agreement for Cetrorelix in Benign Prostatic Hyperplasia

All amounts are in US dollars QUEBEC CITY, March 6 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS ; TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced the signing of a development, commercialization and licensing agreement ...

PDS Biotechnology Corporation Finalizes Commercial Licensing Agreement with Merck Eprova AG to Utilize Merck Eprova's Enantiomers of DOTAP Chloride in Immunotherapies

INDIANAPOLIS, Feb. 24 /PRNewswire/ -- PDS Biotechnology today announced that the company has obtained an exclusive license from Merck Eprova AG to utilize Merck Eprova's proprietary chiral lipid DOTAP Chloride in Versamune(TM)-HPV and other products in development based on the Versamune(TM) te...

Romark and Chugai Pharmaceutical Enter Into Exclusive Licensing Agreement for Nitazoxanide in Japan

Chugai Pharmaceutical Gains Rights to Develop and Market Nitazoxanide for the Treatment of Chronic Hepatitis C TAMPA, Fla., Feb. 17 /PRNewswire/ -- Romark Laboratories, a privately held biopharmaceutical company, and Chugai Pharmaceutical Co. Ltd., a member of the Roche Group, today announced...

Azur Pharma Announces the Licensing of Niravam, Parcopa, Kemstro and Fluxid From UCB

DUBLIN, Ireland, January 9 /PRNewswire/ -- Azur Pharma Limited ("Azur Pharma") today announced that it licensed the exclusive U.S. marketing rights for Niravam(R) (alprazolam orally disintegrating tablets), Parcopa(R) (carbidopa-levodopa orally disintegrating tablets), Kemstro(TM) (baclofen or...

Codexis, Teva in Licensing Agreement Final

REDWOOD CITY, Calif., Jan. 7 /PRNewswire/ -- Codexis, Inc. today announced a licensing agreement with Teva Pharmaceutical Industries Ltd., to produce an important publicly-undisclosed generic product, using a proprietary Codexis biocatalyst. Teva, the largest generic drug manufacturer in the ...

ABAXIS Announces Worldwide Animal Health Licensing Agreement for Rapid Test Technology

UNION CITY, Calif., Jan. 7 /PRNewswire-FirstCall/ -- Abaxis, Inc. (Nasdaq: ABAX ), a medical products company manufacturing point-of-care blood analysis instruments for both the medical and veterinary markets, announced today that it has entered into a license agreement for co-exclusive worldwid...

DSM Biologics and Crucell Announce Commercial PER.C6(R) Licensing Agreement with Gedeon Richter

PARSIPPANY, N.J. and LEIDEN, Netherlands, Nov. 25 /PRNewswire/ -- DSM Biologics, a business unit of DSM Pharmaceutical Products, and Dutch biotechnology company Crucell N.V. (Euronext, Nasdaq: CRXL ; Swiss Exchange: CRX), today announced that Hungary-based Gedeon Richter Plc. signed a commercial...

VisualSonics and Seno Medical Instruments Sign Exclusive Opto-Accoustic Licensing Agreement for Preclinical Research

International Agreement Licenses Seno's Opto-Acoustic Imaging Technology To VisualSonics to Enable Molecular Imaging at the Cellular Level and Aid in the Pursuit of Neurology, Regenerative Medicine, Inflammation, and Cancer Applications TORONTO and SAN ANTONIO, TX, Nov. ...

Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway

LAUSANNE, Switzerland and BANGALORE, India, November 20 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly oncology, and Aurigene Discovery Technologies Ltd (Aurigene), a Bangalore-based fully...

Sigma-Aldrich and the University of Illinois Offer New Boronic Acid Surrogates to Researchers Worldwide Through Licensing Agreement

Technology expected to aid drug discovery by allowing for the rapid synthesis of molecules using a single reaction ST. LOUIS, Oct. 7 /PRNewswire-FirstCall/ -- Sigma-Aldrich (Nasdaq: SIAL) is pleased to announce that it has signed an exclusive licensing agreement with the Universi...

Baxter Announces Licensing Agreement for Innocoll's Gentamicin Surgical Implant in the United States

The antibiotic surgical product may reduce incidence of surgical site infections and reduce post-operative cost and complications DEERFIELD, Ill. and ASHBURN, Va., Aug. 25 /PRNewswire-FirstCall/ -- Baxter Healthcare Corporation today announced a licensing agreement with Innocoll Pharmace...

CEL-SCI Announces Exclusive Licensing Agreement with Teva for Cancer Drug Multikine

VIENNA, Va., Aug. 19 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (Amex: CVM ) announced today that it has entered into an exclusive licensing agreement with Teva Pharmaceutical Industries Ltd. (Teva), a leading global pharmaceutical company, under which CEL-SCI has granted Teva an exclusive...

ArunA Biomedical Announces Exclusive Worldwide Technology Licensing Agreement to Commercialize Human Embryonic Stem Cell Derived Mesenchymal Cells

ATHENS, Georgia, Aug. 19 /PRNewswire/ -- ArunA Biomedical, Inc., a leader in human embryonic stem cell derived products, announced today that it has entered into an exclusive worldwide technology licensing agreement with the University of Georgia Research Foundation that will enable the compan...

GlaxoSmithKline Signs Licensing Agreement With Compendia Bioscience

ANN ARBOR, Mich., June 5 /PRNewswire/ -- Compendia Bioscience today announced that it has signed a two-year licensing agreement with GlaxoSmithKline (NYSE: GSK ) for Oncomine(TM) Enterprise Edition, a value-added product extension Compendia's flagship product, Oncomine. Oncomine Enterprise Ed...

Anesiva and Transcription Factor Therapeutics, Inc. Announce Licensing Agreement for Development and Commercialization of NF-kappa B Clinical Program

SOUTH SAN FRANCISCO, Calif., June 5 /PRNewswire-FirstCall/ -- Anesiva, Inc. (Nasdaq: ANSV ) today announced that it has out-licensed all worldwide rights to its NF-kappa B Decoy (NF-kB Decoy) program, which includes the clinical drug candidate Avrina(TM), to Transcription Factor Therapeutics,...

Boston Scientific and Surgi-Vision Announce Licensing Agreement for MRI-Safe Technology

Emerging technology will potentially enable access to MRI exams for implantable cardiac device patients NATICK, Mass. and BALTIMORE, April 15 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) and Surgi-Vision, Inc., a privately held company, today announc...

AMDL Signs Exclusive Licensing Agreement for Human Papilloma Virus Diagnostic Test Kit in Certain Asian Countries

TUSTIN, Calif., April 3, 2008 /PRNewswire-FirstCall/ -- AMDL, Inc. (Amex: ADL ), headquartered in Tustin, California, with operations in Shenzhen, Jiangxi, and Jilin, China, is a vertically integrated specialty pharmaceutical company. In combination with its subsidiary Jade Pharmaceutical Inc...

Lentigen Corporation Announces Exclusive Licensing Agreement With Case Western Reserve University to Develop Novel Stem-Cell Therapy for Brain Cancer

GAITHERSBURG, Md., March 20 /PRNewswire/ -- Lentigen Corporation today announced an exclusive licensing agreement with Case Western Reserve University (CWRU) in Cleveland, Ohio, to develop a novel stem-cell therapy for glioblastoma, an aggressive type of brain cancer. Under the agreement, Case...

XTL Biopharmaceuticals Signs $108 Million Deal for the Licensing of its Pre- Clinical Program in Hepatitis C to Presidio Pharmaceuticals

VALLEY COTTAGE, N.Y., March 20 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB , TASE: XTL) announced the licensing of its pre-clinical program in Hepatitis C focused on the NS5A target (the "Program") to San-Francisco based Presidio Pharmaceuticals, Inc. Presidio is a pri...

Corgenix Signs Technology Licensing Agreement With Japanese Government

AGREEMENT PROVIDES CORGENIX EXCLUSIVE WORLDWIDE RIGHTS TO DIAGNOSTIC TECHNOLOGY MEASURING SERUM BIO-MARKER FOR CARDIOVASCULAR INFLAMMATION DENVER, March 18 /PRNewswire-FirstCall/ -- Corgenix Medical Corporation (OTC Bulletin Board: CONX), a worldwide developer and marketer of diagnostic t...

Angiotech and Rex Medical announce exclusive licensing and distribution agreement for the "Option(TM)" inferior vena cava filter

VANCOUVER, March 13 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI , TSX: ANP) announced today that it has entered into a definitive licensing agreement with privately held Rex Medical, LP ("Rex Medical") for exclusive worldwide rights to market and distribute the Opti...

ROBODOC(R) Announces Patent Cross Licensing Agreement With IBM

SACRAMENTO, Calif., March 3 /PRNewswire/ -- ROBODOC, a Curexo Technology Company, and IBM announced today that they have entered into a major patent Cross licensing agreement. The terms of the agreement were not disclosed by either party. In addition to its current surgical robotics patents,...

Sigma-Aldrich and MorphoSys Enter Into a Collaboration and Licensing Agreement for Recombinant Research Antibodies

AbD Serotec will use proprietary technology to generate antibodies against novel research targets provided by Sigma-Aldrich MUNICH, Germany and ST. LOUIS, Feb. 27 /PRNewswire-FirstCall/ -- Sigma-Aldrich(TM) (Nasdaq: SIAL ) and MorphoSys AG (Frankfurt Stock Exchange: MOR; Prime Stand...

CV Therapeutics and Medlogics Device Corporation Sign Licensing Agreement for CVT's Innovative Stent Coating Technology

PALO ALTO and SANTA ROSA, Calif., Feb. 4 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX ) and Medlogics Device Corporation announced today that the companies have entered into an agreement under which Medlogics has licensed CV Therapeutics' proprietary biopolymer stent coating ...

mNEMOSCIENCE GmbH Announces Global Licensing Agreement With Aporo Biomedical

- New Deal Advances the Company's Groundbreaking Smart Shape Memory Polymer (BIO-SMP(TM)) Commercialization Program - AACHEN, Germany, Jan. 30 /PRNewswire/ -- mNEMOSCIENCE GmbH, the pioneer in the design, manufacture and commercialization of innovative, biocompatible shape memory p...

Arbor Surgical Technologies Announces Series C Financing and Licensing Agreement with Medtronic

Proceeds to Fund U.S. Clinical Trials of Trilobal Tissue Heart Valve and Implantation Technologies IRVINE, Calif., Jan. 28 /PRNewswire/ -- Arbor Surgical Technologies, Inc., a privately held medical device company, announced today the closing of a $20 million dollar Serie...

Angiotech and Symphony Medical Announce Licensing Agreement

New Clinical Program Under Development to Improve Outcomes of Coronary Artery Bypass Grafting (CABG) and Cardiac Valve Surgeries VANCOUVER, BC and LAGUNA HILLS, CA, Jan. 17 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI , TSX: ANP) and privately held Symphony Me...

Burrill Merchant Banking Advises Faes Farma on Bilastine Licensing Agreement

SAN FRANCISCO, Jan. 9 /PRNewswire/ -- Burrill Merchant Banking acted as exclusive financial advisor to Faes Farma (Spain) on its recently-completed commercial partnering of bilastine with the Menarini Group (Italy). Under the terms of the agreement, Faes has licensed bilastine rights in Europe...

Burrill Merchant Banking Advises NPS on Phase III Licensing Agreement

SAN FRANCISCO, Jan. 9 /PRNewswire/ -- Burrill Merchant Banking acted as exclusive financial advisor to NPS Pharmaceuticals on its recently-completed partnering of Gattex(TM) (teduglutide) with Nycomed. Under the terms of the agreement, NPS has licensed rights to Gattex outside North America to...

Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs

- HGS acquires exclusive rights to develop and commercialize small-molecule IAP inhibitors in oncology - - Lead compound AEG40826 works synergistically with HGS TRAIL receptor antibodies to enhance anticancer activity of both drugs - - IAP inhibitors also show prom...

Lilly and BioMS Medical Announce Global Licensing and Development Agreement

Lilly to Acquire Exclusive Rights to Novel Late-Stage Molecule for the Treatment of Multiple Sclerosis INDIANAPOLIS and EDMONTON, Alberta, Dec. 17 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY ) and BioMS Medical Corp. (TSX: MS) today announced that the two co...

Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001

BALTIMORE, Dec. 14 /PRNewswire/ -- Alba Therapeutics Corporation announced today that it has entered into a strategic collaboration with Shire plc (LSE: SHP, Nasdaq: SHPGY, TSX: SHQ), to jointly develop AT-1001, Alba's lead inhibitor of barrier dysfunction in various gastrointestinal ("GI") di...

Immtech and BioAlliance Sign Licensing Agreement for Pafuramidine

NEW YORK, Dec. 4 /PRNewswire-FirstCall/ -- Immtech Pharmaceuticals, Inc. (AMEX: IMM ) announced today that the Company has granted an exclusive license to BioAlliance Pharma SA (Euronext Paris - ticker code BIO) to commercialize Immtech's oral drug, pafuramidine maleate (pafuramidine), in Eur...

Aureus Pharma Announces Renewal and Expansion of Licensing Agreement With Bristol-Myers Squibb for its AurSCOPE Knowledge Databases

PARIS, November 12 /PRNewswire/ -- Aureus Pharma, a leading provider of knowledge management solutions to accelerate discovery in the life sciences industry, today announced that Bristol-Myers Squibb Company (NYSE: BMY ) has renewed its license to Aureus' AurSCOPE GPCR, and has also licensed ...

Lantibio and TRB Chemedica Announce Licensing Agreement with Alcon for US Development and Marketing of Dry Eye Drug

CHAPEL HILL, N.C., and VALAIS, Switzerland, Nov. 5 /PRNewswire/ -- Lantibio, Inc. and TRB Chemedica announced today the signing of a licensing agreement with a subsidiary of Alcon, Inc. (NYSE: ACL ) for the US development, marketing, and manufacture of a Dry Eye Syndrome product. The product ...

National Stem Cell Holding in Final Stage Negotiations for Exclusive Licensing of its Recently Discovered Biomaterial for Anti-Aging Applications

This development places National Stem Cell in the sector for Anti-aging products and services, presently a $30 Billion Market, and one of the Biggest Marketing Opportunities in the U.S. Today MOUNTAINSIDE, N.J., Oct. 25 /PRNewswire-FirstCall/ -- National Stem Cell Holding, Inc. (O...

BioWa Announces Licensing of BioWa's POTELLIGENT(R) Technology by GlaxoSmithkline for Use in Antibody Research and Development

PRINCETON, N.J., Oct. 19 /PRNewswire/ -- BioWa, Inc. (BioWa) announced today that it has entered into a research agreement which provides GlaxoSmithkline (GSK) with access to BioWa's patented POTELLIGENT(R) Technology platform for the development of antibody-dependent cellular cytotoxicity (AD...

Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan

Deal Includes up to $100MM in License Fees and Potential Milestone Payments NEW YORK, Sept. 26 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ), announced today that it entered into a licensing agreement with Japan Tobacco Inc. (JT) (TSE: 2914) and Torii Pharmaceutical C...